JP2023549555A - 抗marco抗体及びその使用 - Google Patents

抗marco抗体及びその使用 Download PDF

Info

Publication number
JP2023549555A
JP2023549555A JP2023529918A JP2023529918A JP2023549555A JP 2023549555 A JP2023549555 A JP 2023549555A JP 2023529918 A JP2023529918 A JP 2023529918A JP 2023529918 A JP2023529918 A JP 2023529918A JP 2023549555 A JP2023549555 A JP 2023549555A
Authority
JP
Japan
Prior art keywords
seq
sequence
antibody
cdr
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023529918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549555A5 (cg-RX-API-DMAC7.html
Inventor
ナディン ジャーチャン
ミシェル ストレウリ
シー ヤン
リンダ リャン
ベンカタラマン スリラム
ジョシュア ポラック
ブラディスラバ ユリッチ
リネア ヘッグブロム
カラ モヒカ
レナード ジー. プレスタ
サヤンタン ミトラ
Original Assignee
パイオニア イミュノセラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パイオニア イミュノセラピューティクス インコーポレイテッド filed Critical パイオニア イミュノセラピューティクス インコーポレイテッド
Publication of JP2023549555A publication Critical patent/JP2023549555A/ja
Publication of JP2023549555A5 publication Critical patent/JP2023549555A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/003—Arrangements for allocating sub-channels of the transmission path
    • H04L5/0044—Allocation of payload; Allocation of data channels, e.g. PDSCH or PUSCH
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W28/00—Network traffic management; Network resource management
    • H04W28/02—Traffic management, e.g. flow control or congestion control
    • H04W28/08—Load balancing or load distribution
    • H04W28/082—Load balancing or load distribution among bearers or channels
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W74/00—Wireless channel access
    • H04W74/08—Non-scheduled access, e.g. ALOHA
    • H04W74/0833—Random access procedures, e.g. with 4-step access
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023529918A 2020-11-18 2021-11-18 抗marco抗体及びその使用 Pending JP2023549555A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063115272P 2020-11-18 2020-11-18
US63/115,272 2020-11-18
US202163244662P 2021-09-15 2021-09-15
US63/244,662 2021-09-15
PCT/US2021/059955 WO2022109178A1 (en) 2020-11-18 2021-11-18 Anti-marco antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2023549555A true JP2023549555A (ja) 2023-11-27
JP2023549555A5 JP2023549555A5 (cg-RX-API-DMAC7.html) 2024-11-20

Family

ID=81588283

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023529918A Pending JP2023549555A (ja) 2020-11-18 2021-11-18 抗marco抗体及びその使用

Country Status (10)

Country Link
US (3) US11572407B2 (cg-RX-API-DMAC7.html)
EP (1) EP4247419A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023549555A (cg-RX-API-DMAC7.html)
KR (1) KR20230121759A (cg-RX-API-DMAC7.html)
AU (1) AU2021382658A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198579A1 (cg-RX-API-DMAC7.html)
IL (1) IL302874A (cg-RX-API-DMAC7.html)
MX (1) MX2023005841A (cg-RX-API-DMAC7.html)
TW (1) TW202237648A (cg-RX-API-DMAC7.html)
WO (1) WO2022109178A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237648A (zh) 2020-11-18 2022-10-01 美商開拓免疫醫療公司 抗marco抗體及其用途
US20250011410A1 (en) * 2021-11-23 2025-01-09 Invetx, Inc. Anti-ngf antibodies and uses thereof
US20260008844A1 (en) * 2022-09-15 2026-01-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Use of anti-marco antibody with a checkpoint blockade antibody for the treatment of cancer
US20260126450A1 (en) * 2022-10-12 2026-05-07 Massachusetts Institute Of Technology Library-scale methods for polypeptide functional analysis
WO2025102054A1 (en) * 2023-11-09 2025-05-15 Massachusetts Institute Of Technology Methods of screening for secreted functional molecules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013535508A (ja) * 2010-08-13 2013-09-12 ベイラー リサーチ インスティテュート 抗体付きアジュバントを抗原提示細胞に直接的に標的化することをベースにした新規ワクチンアジュバント
US20180171021A1 (en) * 2015-06-01 2018-06-21 The Rockefeller University Anti-Tumor Agents and Methods of Use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916766A (en) 1996-05-23 1999-06-29 Smithkline Beecham Corporation Human marco scavenger receptor
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
US20100227415A1 (en) 2007-07-24 2010-09-09 Iss Immune System Stimulation Ab Method and means for prediction of systemic lupus erythematosus susceptibility
US8597946B2 (en) 2008-03-10 2013-12-03 H. Lee Moffitt Caner Center and Research Institute, Inc. Enhanced dendritic cells for cancer immunotherapy
WO2012122396A1 (en) 2011-03-08 2012-09-13 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
WO2017062363A1 (en) 2015-10-05 2017-04-13 Joslin Diabetes Center Methods of use of betatrophin
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
EP3612563A1 (en) 2017-04-19 2020-02-26 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
TW201904588A (zh) 2017-06-25 2019-02-01 美商西雅圖免疫公司 引導及導航控制蛋白質之製造及使用方法
EP3668899A4 (en) 2017-08-18 2020-09-02 Celdara Medical, LLC CELL-BASED THERAPIES TARGETING DISEASE-ASSOCIATED MOLECULAR MEDIATORS OF FIBROTIC, INFLAMMATORY AND AUTOIMMUNE DISEASES
PL3688155T3 (pl) 2017-09-28 2023-09-11 Immpact-Bio Ltd. Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar)
MX2020006654A (es) 2017-12-22 2020-11-06 Atossa Therapeutics Inc Métodos intraductales de tratamiento de trastornos de mama.
MX387358B (es) 2018-02-28 2025-03-18 Pfizer Variantes de il-15 y usos de las mismas
BR112021006100A2 (pt) 2018-09-28 2021-07-20 Immpact-Bio Ltd. métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer
JP2022514215A (ja) * 2018-12-05 2022-02-10 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ Rankアンタゴニストおよびその使用
EP3906055A4 (en) 2019-01-04 2023-01-04 Trio Pharmaceuticals, Inc. MULTISPECIFIC PROTEIN MOLECULES AND THEIR USES
WO2020162696A1 (ko) 2019-02-08 2020-08-13 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
US20220152148A1 (en) 2019-03-18 2022-05-19 The Broad Institute, Inc. Modulation of type 2 immunity by targeting clec-2 signaling
IL287801A (en) 2019-05-07 2022-07-01 Immunicom Inc Increasing responses to checkpoint inhibitors by extracorporeal apheresis
GB2603044B (en) 2019-06-11 2024-08-21 Myeloid Therapeutics Inc Macrophage specific engager compositions and methods of use thereof
KR20220054305A (ko) 2019-07-31 2022-05-02 온코어 파마, 인크. 면역 회피성 종양의 치료
TW202237648A (zh) 2020-11-18 2022-10-01 美商開拓免疫醫療公司 抗marco抗體及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013535508A (ja) * 2010-08-13 2013-09-12 ベイラー リサーチ インスティテュート 抗体付きアジュバントを抗原提示細胞に直接的に標的化することをベースにした新規ワクチンアジュバント
US20180171021A1 (en) * 2015-06-01 2018-06-21 The Rockefeller University Anti-Tumor Agents and Methods of Use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANNA-MARIA GEORGOUDAKI ET AL.: ""Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and M", CELL REPORTS, vol. 15, no. 9, JPN6025043971, 2016, pages 2000 - 2011, ISSN: 0005865495 *
OUTI ELOMAA ET AL.: ""Structure of the Human Macrophage MARCO Receptor and Characterization of Its Bacteria-binding Regi", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 8, JPN6025043970, 1998, pages 4530 - 4538, ISSN: 0005865494 *

Also Published As

Publication number Publication date
CA3198579A1 (en) 2022-05-27
US20260172900A1 (en) 2026-06-18
WO2022109178A9 (en) 2023-07-13
WO2022109178A1 (en) 2022-05-27
US11572407B2 (en) 2023-02-07
TW202237648A (zh) 2022-10-01
IL302874A (en) 2023-07-01
MX2023005841A (es) 2023-08-16
US12378311B2 (en) 2025-08-05
AU2021382658A1 (en) 2023-07-06
EP4247419A4 (en) 2024-11-06
US20220153832A1 (en) 2022-05-19
EP4247419A1 (en) 2023-09-27
US20240084000A1 (en) 2024-03-14
KR20230121759A (ko) 2023-08-21

Similar Documents

Publication Publication Date Title
JP7069261B2 (ja) Cd73特異的結合分子及びその使用
US12240910B2 (en) Anti-C-C motif chemokine receptor 8 (CCR8) antibodies and methods of use
TWI731861B (zh) FcRH5之人源化及親和力成熟抗體及使用方法
US12378311B2 (en) Anti-MARCO antibodies and uses thereof
JP6931329B2 (ja) 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
JP7688579B2 (ja) 抗trem2抗体の使用方法
KR20230164243A (ko) Icos에 대한 항체
HK1258249A1 (zh) 用於测定icos表达的基因标志
JP7596263B2 (ja) 4-1bb及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
JP7759996B2 (ja) 抗trem1抗体及び関連方法
US20240269176A1 (en) Heterodimeric fc domain antibodies
EP4329806A1 (en) Anti-siglec compositions and uses thereof
HK40096227A (zh) 抗marco抗体和其用途
CN116635073A (zh) 抗marco抗体和其用途
EA052033B1 (ru) Антитела к marco и их применение
Nilvebrant et al. IBC’s 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of the Antibody Society, December 5–8, 2011, San Diego, CA
HK40065337A (en) Anti-trem1 antibodies and related methods
EA049996B1 (ru) Антитело к siglec-10 (варианты)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241112

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260521